Search

Search Constraints

You searched for: Author/Creator Bradbury, Penelope A.

Search Results

1. A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. (May 2020)

2. A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Issue 11 (November 2016)

3. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. (April 2016)

4. ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. (August 2020)

5. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. Issue 2 (November 2015)

6. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. Issue 11 (29th July 2019)

7. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. (June 2018)

8. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. (June 2021)

9. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study. (January 2021)

10. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. (2022)